SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001445305-14-002193
Filing Date
2014-05-15
Accepted
2014-05-15 16:13:22
Documents
10
Period of Report
2014-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20140331x10q.htm 10-Q 679602
2 CERTIFICATION mrtx-20140331xex312.htm EX-31.2 11950
3 CERTIFICATION mrtx-20140331xex311.htm EX-32.1 11220
4 CERTIFICATION mrtx-20140331xex321.htm EX-32.1 7894
  Complete submission text file 0001445305-14-002193.txt   4392727

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mrtx-20140331.xml EX-101.INS 690131
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20140331.xsd EX-101.SCH 29038
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20140331_cal.xml EX-101.CAL 49877
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20140331_def.xml EX-101.DEF 78114
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20140331_lab.xml EX-101.LAB 345673
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20140331_pre.xml EX-101.PRE 180316
Mailing Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 (514) 337-3333
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 14847388
SIC: 2834 Pharmaceutical Preparations